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DIABETES MELLITUS: NEW DEVELOPMENTS AND THEIR IMPLICATION FOR 
A PREVENTION STRATEGY 
• The classification of type I and type II diabetes mellitus 
has been made under the guidance of the World Health Orga- 
nization (WHO) (see WHO report, 1980, and Ref.l). 
Type I or insulin dependent diabetes mellitus (IDDM) is char- 
acterized by absolute insulin deficiency due to an autoimmune 
destructive process of the P-cell in the islets of Langerhans. 
The main clinical symptoms for IDDM are thirst, polyuria 
and acidosis. Antibodies to islets cells are found, while indi- 
cations of residual insulin production (the so-called C-peptide 
levels) appear at low levels at the onset of the disease. Type I 
diabetes can develop at any age (often below 30 years old). 
Genetic factors seem to predispose for the susceptibility to de- 
velop the autoimmune insulitis by viral or other toxic causes 
(2,3). 
The cause of type II or non-insulin dependent diabetes mellitus 
(NIDDM) is not clear. Both insulin resistance and changed 
secretion pattern of insulin can be found. The primary patho- 
logical factor, either insulin resistance or changed insulin se- 
cretion, is unknown. Perhaps they are always coupled. Type II 
diabetes develops slowly, and is marked by high glucose lev- 
els. Ketoacidosis or strong lipolysis is seldom found, while 
insulin and C-peptide levels are high in the early stage of the 
disease. A strong familiar relationship is seen in NIDDM. 
GENETIC FACTORS 
• The predisposition to type I diabetes mellitus is a com- 
plex multigene phenomenon. No single locus has been un- 
equivocally demonstrated to be directly related to the disease. 
Although certain alleles of HLA loci, e.g. the HLA-DQ, are 
candidates, their effects are seemingly not related to presenta- 
tion of the autoantigenic peptide to self-reactive T cells. Their 
function in shaping the T cell repertoire remains to be studied 
(2-4). In the DQB genes, especially the amino acid at position 
57 (Asp
57
), seems to be directly correlated with resistance. 
A better understanding of the genetics and pathogenesis of 
type I diabetes can be obtained by analysis of HLA-haplotypes. 
Extended haplorype, stretches of chromosomes conserved in 
evolution may contain the key to unravel the mechanism of 
genetic predispositions to type I diabetes (4). 
Immunointervention therapy in type I diabetes can be applied 
as long as p-cell destruction is incomplete and p-cell function 
can be preserved. "The most elegant approach of specific in- 
tervention in the p-cell destruction process would only affect 
the component of the immune system involved in this disease 
process" (4). At least two autoimmune targets on pancreatic 




specific immunotherapy could be directed too. 
The genetic defects in type II diabetes are approached in a 
different way. Since insulin is still present in the early phase 
of disease, the attention is more directed towards the genes 
producing proteins involved in the signal transduction (Fig. 1). 
Mutations have been published for insulin receptor genes, in- 
sulin receptor substrate-1 (IRS-1) genes, glucose transporter 
4 (GLUT4), and phosphatidylinositol 3-kinase (PI,-kinase). 
On the genes of enzymes involved in phosphorylation and in 
glycogen synthesis no mutations are published. Some muta- 
tions are found outside the signaling pathway. They concern 
the glucagon receptor gene and the |33-adrenergic receptor 
gene. 
A new subtype of diabetes was described at the end of the 
eighties, maternally inherited diabetes and deafness (MIDD). 
This type of diabetes is characterized by maternal inheritance 
and a hearing disturbance. The maternal inheritance focussed 
research on gene mutations to mitochondrial DNA. A muta- 
tion was found in the position 3234 of mitochondrial DNA 




. A number of proteins involved in the 
respiratory chain complexes are disturbed due to impaired leu- 
cine incorporation (5). 
ENVIRONMENTAL FACTORS 
A higher prevalence rate for type II diabetes is noted for low- 
birth-weight subjects aged 50 to 70 years. Presumably the as- 
sociation between type II diabetes and low weight at birth is 
not related to a coincidence of type II diabetes genotype and a 
genetically determined low birth weight (6). In this respect, 
intrauterine malnutrition, especially protein deficiency, is an 
important factor. Switching from a rural to an urban life style 
increases type II diabetes. The thrifty gene hypothesis says 
that "for societies living in environments with unstable food 
supplies, maximizing storage of surplus energy would enhance 
the probability of survival under periods of energy deficiency. 
  
 
Figure 1. Schematic outline of insulin-induced glucose transport and glycogen synthesis. p85 and pi 10, subunits ofPl- 
kinase; HK- hexokinase; ins - insulin; PTyr -phosphotyrosine; IRS1 - insulin receptor substrate 1; exo - exocytosis; endo 
- endocytosis; GLUT - glucose transporter. Courtesy of Maassen (9) 
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The abundance of food typical for modern Westernized soci- 
ety might lead to marked obesity and glucose intolerance in 
such a genotype" (6). The expression of a diabetic genetic ef- 
fect may also depend on the presence of obesity or reduced 
physical activity in the affected individual. 
PREVENTION OF DIABETES MELLITUS 
A major contribution to improved health status will be pro- 
vided by prevention or delay of diabetes (7). Three main types 
of prevention of diabetes can be distinguished (see WHO re- 
port, 1994): (/) primary prevention is related to the genetic 
changes seen in diabetes, (ii) secondary prevention is related 
to the metabolic changes noted in diabetes, and ( H i )  tertiary 
prevention concerns the development of secondary complica- 
tions. 
To prevent diabetes mellitus the cause of disease must be known 
and treatment must be available. Both conditions cannot be 
met in diabetes. Therefore, prevention of diabetes can only be 
presented as general prevention. However, general informa- 
tion directed to and education of persons identified as high 
risk to develop diabetes mellitus can be more effective. 
LESSONS FOR BULGARIA 
What does this special volume of the Biomedical Reviews mean 
for the prevention and study of diabetes mellitus in Bulgaria? 
Two important recommendations can be made: 
( i )   A public relations campaign has to start on radio and TV 
that indicates the risk factors involved in diabetes mellitus 
as outlined in the WHO report (1994) supported by the 
now free-obtainable insulin and other materials in Bul- 
garia. 
•    General preventive measurements have to be brought 
at the attention of the Bulgarian population. These are: 
(a) increase of physical activity, (b) right choices of 
food and beverages, and (c) reduction of overweight 
•   A special subcampaign has to be directed to persons 
identified as a high risk to develop diabetes mellitus. 
•   Extratraining programmes have to be developed for 
physicians in certain regions in Bulgaria (see Koeva 
and Koev [8] in this volume of Biomedical Reviews). 
( ii ) One or more scientific group(s) in Bulgaria studying dia- 
betes mellitus has (have) to be developed by or related to a 
Diabetes Health Care Center. As can be learned from the 
history of polio in the Netherlands where one scientific 
group working on polio was extremely well involved in 
the polio research of the USA. The former developed in- 
activation and isolation of polio virus in the USA. This 
could be immediately applicated in a vaccination prog- 
(•;; ramme in the Netherlands, protecting several year groups 
.,•;> of Dutch children a head of the same year groups in Bel- 
gium. Compared to Belgium, billions of Dutch guilders 
of health care costs were saved. A National Institute for 
Diabetes must be the place to stimulate the knowledge 
and the care for diabetes as the Saint-Vincent Declaration 
asks that they must be developed in every country. 
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